ChiCTR2400089059 版本V1.0 版本创建时间2024/08/30 17:21:59 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400089059 

最近更新日期:

Date of Last Refreshed on:

2024-08-30 17:21:16 

注册时间:

Date of Registration:

2024-08-30 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

炎性因子水平与心脏术后不良结局的关系

Public title:

relationship between inflammatory biomarkers and outcomes after cardiac surgery

注册题目简写:

English Acronym:

研究课题的正式科学名称:

炎性因子水平对心脏外科术后不良结局的预测价值

Scientific title:

Inflammatory biomarkers to predict clinical outcomes in adults after cardiac surgery

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

刘正琴 

研究负责人:

翟茜 

Applicant:

zhengqin liu 

Study leader:

Zhai Qian 

申请注册联系人电话:

Applicant telephone:

+86 18560086801

研究负责人电话:

Study leader's telephone:

+86 18560081006

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

demi111@163.com

研究负责人电子邮件:

Study leader's E-mail:

13793182152@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

济南市历下区文化西路107号

研究负责人通讯地址:

济南市历下区文化西路107号

Applicant address:

No. 107 Wenhua West Road, Lixia District, Jinan

Study leader's address:

No. 107 Wenhua West Road, Lixia District, Jinan

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

山东大学齐鲁医院

Applicant's institution:

Qilu Hospital of Shandong University

研究负责人所在单位:

山东大学齐鲁医院

Affiliation of the Leader:

Qilu Hospital of Shandong University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KYLL-202308-017

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

山东大学齐鲁医院伦理委员会

Name of the ethic committee:

Ethics Committee of Qilu Hospital of Shandong University

伦理委员会批准日期:

Date of approved by ethic committee:

2023-09-01 00:00:00

伦理委员会联系人:

卜丽娟

Contact Name of the ethic committee:

Bu LiJuan

伦理委员会联系地址:

济南市历下区文化西路107号

Contact Address of the ethic committee:

No. 107 Wenhua West Road, Lixia District, Jinan

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 531 82169166

伦理委员会联系人邮箱:

Contact email of the ethic committee:

bulijuan16@sdu.edu.cn

研究实施负责(组长)单位:

山东大学齐鲁医院

Primary sponsor:

Qilu Hospital of Shandong University

研究实施负责(组长)单位地址:

济南市历下区文化西路107号

Primary sponsor's address:

No. 107 Wenhua West Road, Lixia District, Jinan

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山东

市(区县):

Country:

China

Province:

Shandong

City:

单位(医院):

山东大学齐鲁医院

具体地址:

济南市历下区文化西路107号

Institution
hospital:

Qilu Hospital of Shandong University

Address:

No. 107 Wenhua West Road, Lixia District, Jinan

经费或物资来源:

自筹

Source(s) of funding:

Self-funded

Target disease:

Postoperative complications in cardiac surgery

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

观察心脏外科术后患者血清炎性因子水平与临床不良结局的关系及其预测价值  

Objectives of Study:

To study the association between perioperative inflammatory cytokines level and clinical outcomes in adults after cardiac surgery and its predictive value

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.2022.4.1-2022.5.31 期间入住心外监护室的心脏外科术后患者; 2.年龄>18 岁。

Inclusion criteria

1. Patients who underwent cardiac surgery and were admitted to the external cardiac care unit between 1.2022.4.1 and May 31, 2022; 2. Age>18 years old.

排除标准:

(1)既往有慢性肾病病史;(2)术前接受肾移植或肾脏透析的患者;(3)术前2周内接触过肾毒性药物

Exclusion criteria:

(1) History of chronic kidney disease in the past; (2) Patients who undergo preoperative kidney transplantation or kidney dialysis; (3) Exposure to nephrotoxic drugs within 2 weeks prior to surgery

研究实施时间:

Study execute time:

From 2023-09-01 00:00:00 To 2024-08-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-09-01 00:00:00 To 2024-08-31 00:00:00  

干预措施:

Interventions:

组别:

体外循环组/ 非体外循环组

样本量:

210

Group:

Extracorporeal circulation group/non extracorporeal circulation group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

山东 

市(区县):

 

Country:

China 

Province:

Shandong 

City:

 

单位(医院):

山东大学齐鲁医院 

单位级别:

三级甲等 

Institution
hospital:

Qilu Hospital of Shandong University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

炎性因子

指标类型:

主要指标

Outcome:

inflammatory biomarkers

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

围术期相关因素

指标类型:

次要指标

Outcome:

perioperative factors

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

机械通气时间延长;术后AKI;30天内死亡

指标类型:

主要指标

Outcome:

prolonged mechanical ventilation , postoperative AKI and 30-day mortality

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

none

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2024-08-30 17:21:16